The inactivation of and via promoter methylation has been investigated in various cancers. However, the clinical effects of and promoter methylation on renal cell carcinoma (RCC) remain to be clarified. The pooled data were calculated and summarized. Finally, an investigation of 14 eligible studies with 1231 RCC patients and 689 control patients was performed. Methylated and were observed to be significantly higher in RCC than in control subjects without malignancies (OR = 2.77, P = 0.005; OR = 11.73, P < 0.001, respectively). Methylated was significantly associated with the risk of RCC in the tissue subgroup, but not in the serum and urine subgroups. Methylated was significantly associated with tumor size. We did not find that promoter methylation was associated with sex, tumor grade, lymph node status, and tumor histology. Methylated was significantly correlated with sex and tumor histology. Three studies reported that methylation was not significantly correlated with the prognosis of RCC. The results suggested that and promoter methylation may be correlated with the carcinogenesis of RCC, and that methylated , especially, can be a major susceptibility gene. We also found the different clinicopathological significance of and in RCC. Additional studies with sufficient data are essential to further evaluate the clinical features and prognostic effect of and promoter methylation in RCC.